Global Ocular Inflammation Market Driven by Environmental Pollution

Increasing contamination of environment by emission of toxins has elevated the risks of ocular inflammation, also known as uveitis. Evolving medical technologies and drug discovery developments have paved way for effective treatment of ocular inflammation. A range of options for treatment of ocular inflammation are being offered to patients – mild inflammations are being treated by the use of corticosteroid eye drops, while oral administration of immunosuppressive agents is being preferred to treat posterior uveitis in both eyes.

global ocular inflammation treatment market

As global pollution levels soar uncontrollably, future generations will be more susceptible to eye inflammations, putting stress on healthcare industry participants in creating affordable and accessible avenues for adopting ocular inflammation treatments. Transparency Market Research foresees that by the end of 2026, over US$ 1 billion worth of revenues will be generated by the sales of drugs and adoption of medical procedures for ocular inflammation treatment.

Currently, the incidence of such sight-impairing disorders is witnessing a sharp increase instrumented by multiple causes, from autoimmunity problems and bruising the eyes to infections occurring near the eye. Toxins penetrating the eyes are observed as the foremost factor driving the global incidence rate of uveitis in the coming years. During the period, 2017-2026, the global market for ocular inflammation treatment will be reflecting a high value growth at a CAGR of 6.9%.

By 2026-end, over US$ 300 million worth of corticosteroids will be used for ocular inflammation treatment

In 2018 and beyond, majority of uveitis patients will be using corticosteroid eye drops for treating their eye inflammations. Considering how ocular inflammation at the back of eyes can become extremely severe if unattended, corticosteroid eye drops are being viewed as the most affordable, convenient and effective treatment for such ocular inflammations.

50% of ocular inflammation treatments will be directed towards anterior uveitis

Anterior uveitis is characterized by its localization – front of the eye, making it the most common form of ocular inflammation in the world. Young and middle-aged demographics are most susceptible to anterior ocular inflammation. Severity of anterior uveitis can also lead to lung infections, gastrointestinal problems and rheumatologic diseases. By 2026-end, more than US$ 530 million worth of ocular inflammation treatments will be used to cure anterior uveitis.

High Uptake Combination Therapies to Drive Discovery of New Drugs on Ocular Inflammation Treatment

For long-term effectiveness, majority of ocular inflammation patients are preferring combination therapy, wherein therapeutic procedures are supported by a prescribed intake of medicines and pharmaceutical drugs. In mid-2017, the FDA’s uveitis pipeline has witnessed the emergence of new drugs & therapies, which include ADX-2 or NS2 by Aldeyra Therapeutics, a dexamethasone implant developed called Ozurdex developed by Allergan, and fluocinolone inserts such as Medidur by pSivida.

In the coming years, majority of products and therapies on ocular inflammation treatments will be developed by companies namely, Allergan Plc., Valeant Pharmaceuticals International, Inc., Novartis AG, Abbvie, Inc., Eyegate Pharmaceuticals, Inc., Alimera Sciences, Inc., pSivida Corporation, Cipla Ltd., Pfizer, Inc., and Akorn, Inc. Novel injection techniques will be introduced for treating ocular inflammations with new formulations. Through 2026, several market players will also focus on discovering new local steroidal agents to treat non-infectious ocular inflammations.

Ocular Inflammation Treatment: Global Market Overview

Eye inflammations or uveitis are becoming a common problem for people across global geographies. New drugs are being discovered to treat ocular inflammations, and companies are investing millions for their approval through regulatory pipelines. Patients are exhibiting a particular preference to the type of ocular inflammation treatment being adopted, considering the range of treatment options, their comparative effectiveness, and convenience in terms of mode of administration. The global market for ocular inflammation treatment is expected to grow sharply in the coming years. Prominent market players are diversifying their product lines to cater treatment of all forms of uveitis occurring worldwide.  

Transparency Market Research’s latest report offers key insights on how the global ocular inflammation treatment market will expand during the forecast period, 2017-2026. This report sheds qualitative information and forecasted market size evaluations on the global ocular inflammation treatment market expansion for the assessment period.  

Key Offerings of the Report

There are a range of advantages of availing this TMR study, particularly for companies interested in expanding their stakes in the global ocular inflammation treatment market. A constant dialogue industry leaders, opinion makers, trade analysts and market participants has generated volumes of data, which has been analyzed across multiple parameters during the development of this study.

An all-embracive research methodology employed for developing accurate forecast on the global ocular inflammation treatment market offers insights in terms of:

  • changing stance of the FDA on uveitis drugs
  • causative factors triggering the incidence of eye inflammations across the globe
  • initiatives of governments in promoting awareness through uveitis programs
  • contribution of medical research organizations towards developing new therapies that extend the use of ocular inflammation drugs
  • addressing the instances that cite ineffectiveness of particular ocular inflammation treatments

From pricing and cost structure to supply chain characteristics, the report supplying objective information on how the global ocular inflammation treatment market will evolve in the coming years. This information has been validated through authentic quality checks and data screening processes. New opportunities for market growth have been revealed, and a slew of first-hand information makes this report a valuable document for companies aiming to expand their business in the ocular inflammation treatment market.

Global Ocular Inflammation Treatment Market: Segmental Breakdown


Treatment Type

Disease Type

Mode of Administration

Distribution Channel

North America


Anterior Uveitis


Hospital Pharmacies

Latin America


Posterior Uveitis


Retail Pharmacies


Monoclonal Antibodies

Pan uveitis


Online Pharmacies



Intermediate Uveitis


Drug Stores


Cycloplegic Agents



















(Additional information, including cross-sectional data and country-wise analysis & forecast is available in the report)

Assessing Details on Key Market Stakeholders

The presence of pharmaceutical industry leaders is fairly consolidated in the global market for ocular inflammation treatments. The report has profiled these market players extensively, tracking their growth till data and tracing their strategic developments in the recent past. Unbiased analysis of such information has generated insights on how a particular pharmaceutical company will take steps towards expanding its stake in the local as well as global ocular inflammation treatment markets.

The current stance of the FDA towards clearing the uveitis pipelines has also been addressed while measuring the potential of companies in contributing immensely towards the future of global ocular inflammation treatment market. Information on their investments portfolio, R&D undertakings and mergers & acquisitions has been summarized to extend the understanding of companies in terms of competitor analysis. The overall scope of this report is to ensure that key companies in the global ocular inflammation treatment market take informed steps towards future market direction.